These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 17401132

  • 1. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
    Smith N, Gadsby K, Butt S, Deighton C.
    Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
    [No Abstract] [Full Text] [Related]

  • 2. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
    Jois RN, Gaffney K, Keat A.
    Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
    [No Abstract] [Full Text] [Related]

  • 3. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
    Temel M, Atagündüz P, Direskeneli H.
    Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
    [No Abstract] [Full Text] [Related]

  • 4. Switching anti-TNF therapy in ankylosing spondylitis.
    Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C.
    Rheumatology (Oxford); 2008 Nov; 47(11):1726-7. PubMed ID: 18782856
    [No Abstract] [Full Text] [Related]

  • 5. BSR guidelines for TNF blockers in ankylosing spondylitis--how useful are they?
    Sheehy C, Murphy E, Barry M.
    Rheumatology (Oxford); 2006 Sep; 45(9):1176-7; author reply 1177-8. PubMed ID: 16820380
    [No Abstract] [Full Text] [Related]

  • 6. TNF inhibitors for ankylosing spondylitis in the real world.
    McVeigh CM, Bell AL, Cairns AP.
    Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
    [No Abstract] [Full Text] [Related]

  • 7. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Sieper J, Rudwaleit M.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
    [Abstract] [Full Text] [Related]

  • 8. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract] [Full Text] [Related]

  • 9. TNF therapy for spondyloarthropathy: can we marshal the argument?
    Dawes PT, Packham JC, Mucklow JC.
    Rheumatology (Oxford); 2004 Sep; 43(9):1069-71. PubMed ID: 15280568
    [No Abstract] [Full Text] [Related]

  • 10. Physical therapy in anti-TNF treated patients with ankylosing spondylitis.
    Dubey SG, Leeder J, Gaffney K.
    Rheumatology (Oxford); 2008 Jul; 47(7):1100-1. PubMed ID: 18495822
    [No Abstract] [Full Text] [Related]

  • 11. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S.
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
    Kiltz U, Heldmann F, Baraliakos X, Braun J.
    Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
    [Abstract] [Full Text] [Related]

  • 13. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F, Miranda-Filloy JA, López-Mejias R, Carnero-López B, Ochoa R, Rueda J, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.
    Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
    [No Abstract] [Full Text] [Related]

  • 14. [Spondyloarthritis].
    Sieper J.
    Z Rheumatol; 2004 Jun; 63(3):185-6. PubMed ID: 15224220
    [No Abstract] [Full Text] [Related]

  • 15. The treatment of ankylosing spondylitis.
    Scalapino KJ, Davis JC.
    Clin Exp Med; 2003 Feb; 2(4):159-65. PubMed ID: 12624705
    [Abstract] [Full Text] [Related]

  • 16. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H.
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract] [Full Text] [Related]

  • 17. Evidence in support of the validity of the TNF brake hypothesis.
    Maksymowych WP.
    Ann Rheum Dis; 2013 Dec; 72(12):e31. PubMed ID: 23989987
    [No Abstract] [Full Text] [Related]

  • 18. Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.
    Kassimos DG, Garyfallos A, Delamere J, Whallett A, Kitas GD.
    Rheumatology (Oxford); 2003 Mar; 42(3):490. PubMed ID: 12626807
    [No Abstract] [Full Text] [Related]

  • 19. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E.
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract] [Full Text] [Related]

  • 20. Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab.
    Gomes KW, Benevides AN, Vieira FJ, Burlamaqui MP, Vieira Mde A, Fontenelle LM.
    Rev Bras Reumatol; 2012 May; 52(3):447-52. PubMed ID: 22641598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.